BMC Ophthalmol:与无虹膜相关的一个新的PAX6突变

2019-01-19 MedSci MedSci原创

南昌大学第二附属医院眼科的Qiu Jijie和上海市第十人民医院眼科的Geng Zhixin等人合作,在BMC Ophthalmol杂志上发表了一篇研究论文,他们讨论了具有常染色体显性遗传性无虹膜的四代中国家庭的临床表征和致病遗传缺陷。

南昌大学第二附属医院眼科的Qiu Jijie和上海市第十人民医院眼科的Geng Zhixin等人合作,在BMC Ophthalmol杂志上发表了一篇研究论文,他们讨论了具有常染色体显性遗传性无虹膜的四代中国家庭的临床表征和致病遗传缺陷。

他们招募其家庭成员,对其进行全面的常规检查和眼科检查,并进行了Sanger测序以筛选PAX6中的突变。

结果发现,在所有受影响的个体中,鉴定出外显子7中的新的杂合PAX6缺失,c.435_445delTAGCGAAAAGC(p.Ser146ThrfsX9),但是在任何未受影响的家族成员和其他200个无关对照患者中都没有这种缺失。

因此,研究人员认为,在与无虹膜相关的中国家族中,他们鉴定出了PAX6基因的新缺失。这扩展了PAX6突变的谱系和其相关表型。

原文出处:

Qiu, J.J., et al., Identification of a novel PAX6 mutation in a Chinese family with aniridia. BMC Ophthalmol, 2019. 19(1): p. 10.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1754784, encodeId=dd2e1e54784d5, content=<a href='/topic/show?id=efff8856504' target=_blank style='color:#2F92EE;'>#虹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88565, encryptionId=efff8856504, topicName=虹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab9a36785616, createdName=LSJ123, createdTime=Sat Feb 23 03:28:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974880, encodeId=f36f19e4880ca, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jun 20 03:28:00 CST 2019, time=2019-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786790, encodeId=77e61e8679088, content=<a href='/topic/show?id=04501380e87' target=_blank style='color:#2F92EE;'>#PAX6突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13807, encryptionId=04501380e87, topicName=PAX6突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Mon Nov 18 07:28:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541429, encodeId=26d0154142907, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Mon Jan 21 04:28:00 CST 2019, time=2019-01-21, status=1, ipAttribution=)]
    2019-02-23 LSJ123
  2. [GetPortalCommentsPageByObjectIdResponse(id=1754784, encodeId=dd2e1e54784d5, content=<a href='/topic/show?id=efff8856504' target=_blank style='color:#2F92EE;'>#虹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88565, encryptionId=efff8856504, topicName=虹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab9a36785616, createdName=LSJ123, createdTime=Sat Feb 23 03:28:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974880, encodeId=f36f19e4880ca, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jun 20 03:28:00 CST 2019, time=2019-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786790, encodeId=77e61e8679088, content=<a href='/topic/show?id=04501380e87' target=_blank style='color:#2F92EE;'>#PAX6突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13807, encryptionId=04501380e87, topicName=PAX6突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Mon Nov 18 07:28:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541429, encodeId=26d0154142907, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Mon Jan 21 04:28:00 CST 2019, time=2019-01-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1754784, encodeId=dd2e1e54784d5, content=<a href='/topic/show?id=efff8856504' target=_blank style='color:#2F92EE;'>#虹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88565, encryptionId=efff8856504, topicName=虹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab9a36785616, createdName=LSJ123, createdTime=Sat Feb 23 03:28:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974880, encodeId=f36f19e4880ca, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jun 20 03:28:00 CST 2019, time=2019-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786790, encodeId=77e61e8679088, content=<a href='/topic/show?id=04501380e87' target=_blank style='color:#2F92EE;'>#PAX6突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13807, encryptionId=04501380e87, topicName=PAX6突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Mon Nov 18 07:28:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541429, encodeId=26d0154142907, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Mon Jan 21 04:28:00 CST 2019, time=2019-01-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1754784, encodeId=dd2e1e54784d5, content=<a href='/topic/show?id=efff8856504' target=_blank style='color:#2F92EE;'>#虹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88565, encryptionId=efff8856504, topicName=虹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab9a36785616, createdName=LSJ123, createdTime=Sat Feb 23 03:28:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974880, encodeId=f36f19e4880ca, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jun 20 03:28:00 CST 2019, time=2019-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786790, encodeId=77e61e8679088, content=<a href='/topic/show?id=04501380e87' target=_blank style='color:#2F92EE;'>#PAX6突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13807, encryptionId=04501380e87, topicName=PAX6突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Mon Nov 18 07:28:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541429, encodeId=26d0154142907, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Mon Jan 21 04:28:00 CST 2019, time=2019-01-21, status=1, ipAttribution=)]

相关资讯

Nat Human Behav:心理暗示会“跑赢”遗传基因?Yes!

一项新研究发现,了解遗传风险会改变一个人的心理,不管他们实际上是什么遗传变异。

Nat Commun:是男,是女,可不是XY染色体说了算这么简单……

X+Y染色体=男性?Science之后,这个等式又被否了!

Cancer Gene Therapy:ERCC6L能够增强细胞活力和促进肿瘤生长

肾细胞癌(RCC)是世界范围内最常诊断的泌尿道恶性肿瘤之一通常与遗传和细胞过程的异常有关。最近,有研究人员通过分析癌症基因组(TCGA)数据库,筛选出了ERCC6L作为一个候选基因。与正常肾组织相比,ERCC6L在ccRCC组织中表达量的增加,因此它可能与RCC的发展有关,并且可能与癌症的预后相关。证据表明ERCC6L是哺乳动物细胞分裂的一个不可缺少的重要组分,但是并没有表明ERCC6L在致瘤中的

PNAS:中疾控合作团队发现同亚型不同簇HIV-1具不同免疫损伤力及其发生机理

中疾控邵一鸣团队早先报道过中国性传播艾滋病起源于泰国CRF01AE亚型的多个流行簇(C1-C8),引起当前艾滋病流行三大病毒簇包括,在异性人群传播的1簇(C1)和男同性恋(MSM)人群传播的4簇和5簇(C4、C5)。

Oncogene:Kras突变能够诱导的CD24表达上调能够增强前列腺癌的多能性和骨转移

前列腺癌(PCA)在男性中是一种最常见的恶性肿瘤之一,并且是世界范围内导致男性死亡癌症中第二大诱因。最近,有研究人员报道了具有条件LSL/KrasG12DP或者BRAFF-V600E等位基因的PCA模型且携带前列腺特异性p53功能缺失能够概括反应人类PCA前期病变、组织病理学和临床行为。研究人员发现类EMT表型和骨转移行为的发展和重新编程需要Kras激活和p53缺失的同时发生。来源于这些模型的原发

JNCI:20年研究证明:维生素E降低or提高癌症的风险和基因有关

近年来,关于维生素补充剂是否有效的研究很多。2018年上半年,生物探索先后报道了维生素D降低患癌风险、治疗糖尿病、提高出生几率等方面的好消息;然而,下半年维生素D不太可能保护个体免受多发性硬化症、帕金森病、阿尔茨海默症或其他大脑相关疾病的侵害,维生素D和鱼油对于健康人也没有明显降低心脏病或癌症风险的能力等相关新闻纷至沓来。